- Home
- TS vs ILMN Comparison
TS vs ILMN Comparison
Compare TS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TS
- ILMN
- Stock Information
- Founded
- TS 2001
- ILMN 1998
- Country
- TS Luxembourg
- ILMN United States
- Employees
- TS N/A
- ILMN N/A
- Industry
- TS Steel/Iron Ore
- ILMN Medical Specialities
- Sector
- TS Industrials
- ILMN Health Care
- Exchange
- TS Nasdaq
- ILMN Nasdaq
- Market Cap
- TS 18.8B
- ILMN 16.0B
- IPO Year
- TS N/A
- ILMN 2000
- Fundamental
- Price
- TS $36.52
- ILMN $101.80
- Analyst Decision
- TS Buy
- ILMN Buy
- Analyst Count
- TS 5
- ILMN 16
- Target Price
- TS $43.20
- ILMN $125.31
- AVG Volume (30 Days)
- TS 1.4M
- ILMN 1.8M
- Earning Date
- TS 07-30-2025
- ILMN 07-31-2025
- Dividend Yield
- TS 4.54%
- ILMN N/A
- EPS Growth
- TS N/A
- ILMN N/A
- EPS
- TS 1.84
- ILMN 7.91
- Revenue
- TS $11,768,597,000.00
- ILMN $4,284,000,000.00
- Revenue This Year
- TS N/A
- ILMN N/A
- Revenue Next Year
- TS N/A
- ILMN $2.78
- P/E Ratio
- TS $9.34
- ILMN $12.87
- Revenue Growth
- TS N/A
- ILMN N/A
- 52 Week Low
- TS $27.59
- ILMN $68.70
- 52 Week High
- TS $40.87
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- TS 53.13
- ILMN 55.53
- Support Level
- TS $35.54
- ILMN $99.08
- Resistance Level
- TS $36.23
- ILMN $102.80
- Average True Range (ATR)
- TS 0.57
- ILMN 2.73
- MACD
- TS 0.08
- ILMN 0.05
- Stochastic Oscillator
- TS 89.03
- ILMN 83.33
About TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.